On October 8, 2026, Berlin-based Clue (made by BioWink GmbH) launched Get Care, a free in-app feature that connects users of its period and cycle tracker directly to vetted care providers. It covers contraception, conception, metabolic and mental health, perimenopause and at-home testing. Clue calls it the first time a mass-market cycle tracker has linked users to care across this many areas of women's health from inside the app. Get Care is live today for users in the UK, US and Germany, with more partners, care areas and markets to follow.

Why It Matters

This is the business-model shift cycle trackers have been working toward: from subscription plus data to **distribution**. A tracker with 100M+ opted-in users sees a contraception decision, a fertility question or the first signs of perimenopause before any clinician does, which makes it a very valuable top of funnel. Get Care formalizes that. It follows Clue's late-September [Flora fertility-insurance partnership](/stories/flora-fertility-clue-partnership) and makes Clue a referral marketplace for telehealth contraception, at-home testing and, through Novo Nordisk and Embla, the GLP-1-adjacent metabolic-health market. Two things will decide whether that trust holds. The first is **economics and disclosure**. The announcement doesn't say whether partners pay Clue per referral. That matters for a company whose then-CEO publicly said in 2024 that it "would not give up" user data to U.S. law enforcement, because the app now has commercial incentives attached to every symptom log. The second is **evidence**. *The BMJ's* recent critique of [menstrual-tracking apps](/stories/bmj-menstrual-tracking-apps-harm) argued they lack proof of benefit, and a pharma partnership on perimenopausal metabolic health will get the same scrutiny. If Get Care converts, rival trackers have every reason to build their own care marketplaces.

The partner list maps out where the femtech referral market is. Per the company's announcement: TwentyEight Health, Evaro, TeleClinic and inne for contraception; Plan Your Baby for fertility and conception; Hertility for at-home hormone and fertility testing; Embla for weight and metabolic health, with Evaro adding weight management in November; and Navicare for mental-health booking. In November, Evaro will also start offering perimenopause and menopause care through Get Care. Behind that sits a life-sciences layer. Clue says it is working with Novo Nordisk to help women "better understand their metabolic health, including during perimenopause." Clue says every partner is vetted on three principles: evidence-based with regulatory clearance where required, a commitment to access and insurance coverage where possible, and enough options to give users real choice.

"Women should not have to do all the work of connecting what they know about their bodies with the care available to them," said Clue CEO Rhiannon White. "Every partner is vetted, and the decision is always the user's to make." Clue cites its own survey of nearly 12,000 users. Two-thirds reported concerns about their menstrual health and most were managing symptoms on their own, and nearly one in four new users said collecting symptoms to share with a clinician is a main reason they join. Clue says it has more than 100 million users in 190 countries.

Sources

Sourcing note: the first two links carry the company's own announcement; no independent trade coverage was available at publication.

Update — 2026-10-09

Initial entry — story first created.